Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.
about
Tumor-specific Th17-polarized cells eradicate large established melanomaTargeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer TypeInterleukin-18 may lead to benign prostatic hyperplasia via thrombospondin-1 production in prostatic smooth muscle cellsPathogenic intestinal bacteria enhance prostate cancer development via systemic activation of immune cells in mice.Prostate cancer and inflammation: the evidence.Elevated pleural effusion IL-17 is a diagnostic marker and outcome predictor in lung cancer patients.Inhibition of chronic prostate inflammation by hyaluronic acid through an immortalized human prostate stromal cell line model.Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.Interleukin-17 Indirectly Promotes M2 Macrophage Differentiation through Stimulation of COX-2/PGE2 Pathway in the Cancer Cells.Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastomaInterleukin-17 Induces Expression of Chemokines and Cytokines in Prostatic Epithelial Cells but Does Not Stimulate Cell Growth In Vitro.Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in ratsAge-related increase in IL-17 activates pro-inflammatory signaling in prostate cells.IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma.CCAAT/enhancer binding protein-δ expression by dendritic cells regulates CNS autoimmune inflammatory disease.Increased chemokine receptor IL-17RA expression is associated with poor survival in gastric cancer patients.Increased infiltrated macrophages in benign prostatic hyperplasia (BPH): role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferationDoes Inflammation Mediate the Obesity and BPH Relationship? An Epidemiologic Analysis of Body Composition and Inflammatory Markers in Blood, Urine, and Prostate Tissue, and the Relationship with Prostate Enlargement and Lower Urinary Tract Symptoms.Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer.Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.Inflammation in prostate carcinogenesis.A novel murine model of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) induced by immunization with a spermine binding protein (p25) peptide.The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease.Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models.Expression of interleukin-17RC protein in normal human tissuesHyperinsulinemia enhances interleukin-17-induced inflammation to promote prostate cancer development in obese mice through inhibiting glycogen synthase kinase 3-mediated phosphorylation and degradation of interleukin-17 receptor.A signaling network in phenylephrine-induced benign prostatic hyperplasia.Inflammatory Mechanisms Associated with Prostatic Inflammation and Lower Urinary Tract SymptomsRole of interleukins, IGF and stem cells in BPHProstate autoimmunity: from experimental models to clinical counterparts.Up for Mischief? IL-17/Th17 in the tumour microenvironment.Inflammation and benign prostatic hyperplasia: clinical implications.Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials.The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH).The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancerBenign prostatic hyperplasia: a new metabolic disease?The role of interleukin-17A in psoriatic disease.Nonsteroidal anti-inflammatory drugs and prostatic diseasesIL-17 Expression by macrophages is associated with proliferative inflammatory atrophy lesions in prostate cancer patients.The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy.
P2860
Q24648032-4E7BBFED-1173-4807-B000-128AF643C329Q28066522-37382DFF-0235-4900-9D92-36E1BF47B24EQ28118871-C7DEE31C-0F82-4D87-9B92-718E1F314CF2Q31133887-B6CB2DA9-D5E5-4B90-8F8D-553C02E6D802Q33642321-1E0F309A-16D6-480E-942D-A496C87D942AQ33698128-20DF01A9-D4EE-44D7-BC80-1F6973B43D46Q33739217-07FCD43C-85A7-442B-BDB8-056A725AF40DQ33741548-416C9067-E9EA-44EF-8520-CD182C9C4286Q34043416-878E07BB-FE77-4E66-8237-EAFC65C3D554Q34132833-885BBF03-38DB-418A-A08F-920CABAAF9D6Q34269107-4AF7CA58-8FEC-4942-93E9-A36BD62E1F51Q35468651-9A5B0A40-0369-4CED-8323-5E5CEB3BCA5FQ35538312-4FD40F60-B705-401F-969E-55504BCFF2E2Q35847817-F8F672BC-13CB-4C6D-8C39-1820107FC196Q35906729-EE38C522-5393-48BD-A597-77BD3EA0E6C6Q35919243-73E5DF12-D5DF-48C8-8470-22A11E7F63D3Q36003050-B838D597-12E6-4E21-A413-AC455652BF3DQ36059979-2FC495FF-AD4A-4129-99CD-C570BC6DC640Q36242082-817ED1F7-E400-4FA0-B8ED-8A2CCC996A8FQ36298863-A5F40CC3-ECE5-4EEA-A6A4-E8721EEB89E8Q36554784-05699140-9270-4213-B1D9-6CE14921A548Q36700297-1CBB92F3-80F5-4F15-B18D-050BC6F3989AQ36747499-C75DFFCC-38BA-40A8-B13E-A2C0AEDB43C7Q36879626-477E16F8-25C2-4924-9422-332D60B7E904Q36999576-0E47691B-C276-4B9A-8B3C-5DBFD41E660FQ37046424-F1E52F3E-D2C8-4478-9F6D-E5293B77F85BQ37281184-F9F6BAA8-5973-4A6B-A365-08F96791580AQ37376015-5A6E14AA-3C74-4814-BCCE-70667F62F413Q37416239-47EB0CFB-1062-4763-9992-F0F30832F1ABQ37755285-6D8E7FB8-0168-413F-B31E-A15037360761Q37781690-D227C5F3-973C-4F33-85C4-6B8B63C7ED78Q37868983-ABA11C42-8188-4B42-8437-DB3094646AF0Q38077302-657EBE31-C5F3-46FC-A916-93112B9C9943Q38104737-8D29E235-C536-4232-8F87-C11E5155922BQ38176621-A09D77FC-3CCD-4C82-B3F6-98330D538CA4Q38181426-5C06150E-5B6D-4EF2-8046-8958F5D429ABQ38217029-0932EC6C-6849-4DFB-8F00-6486E6317911Q38217858-8113480D-1529-4A3B-AA8E-DECA19BBBDD7Q38256438-6F4EFDD5-5B9B-4606-A84F-C5BBD1A83482Q38259866-96E5CB1B-FFE1-45CA-8D8E-8B44AE8734EF
P2860
Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Expression and function of pro ...... astic, and malignant prostate.
@ast
Expression and function of pro ...... astic, and malignant prostate.
@en
Expression and function of pro ...... astic, and malignant prostate.
@nl
type
label
Expression and function of pro ...... astic, and malignant prostate.
@ast
Expression and function of pro ...... astic, and malignant prostate.
@en
Expression and function of pro ...... astic, and malignant prostate.
@nl
prefLabel
Expression and function of pro ...... astic, and malignant prostate.
@ast
Expression and function of pro ...... astic, and malignant prostate.
@en
Expression and function of pro ...... astic, and malignant prostate.
@nl
P2093
P2860
P356
P1433
P1476
Expression and function of pro ...... lastic, and malignant prostate
@en
P2093
Doris Paikl
Georg E Steiner
Martin E Newman
Michael J Marberger
Ursula Stix
P2860
P304
P356
10.1002/PROS.10238
P577
2003-08-01T00:00:00Z